The Bill & Melinda Gates Foundation will invest up to $40 million in a collaboration with Immunocore, a T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases, and autoimmune diseases. The investment will support the development of Immunocore s solubleOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.